DiaMedica Therapeutics Inc.
DMAC· Nasdaq
Released Aug 7, 2024, after the close
10-Q filed Aug 7, 2024, 38 days after period end · 0001437749-24-025198
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$5.12M | -$4.48M | -$3.36M | -$3.27M |
| EPS Diluted | — | — | — | -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DiaMedica Therapeutics Inc. · CIK 1401040 · Engraved from SEC EDGAR